The Math Shows XBI Can Go To $116

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $115.79 per unit.

START SLIDESHOW:
10 ETFs With Most Upside To Analyst Targets »

With XBI trading at a recent price near $84.59 per unit, that means that analysts see 36.88% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of XBI's underlying holdings with notable upside to their analyst target prices are Iovance Biotherapeutics Inc ( IOVA), Cytokinetics Inc ( CYTK), and Abeona Therapeutics Inc ( ABEO). Although IOVA has traded at a recent price of $8.25/share, the average analyst target is 92.92% higher at $15.92/share. Similarly, CYTK has 87.66% upside from the recent share price of $8.45 if the average analyst target price of $15.86/share is reached, and analysts on average are expecting ABEO to reach a target price of $29.71/share, which is 87.47% above the recent price of $15.85. Below is a twelve month price history chart comparing the stock performance of IOVA, CYTK, and ABEO:

IOVA, CYTK, and ABEO Relative Performance Chart

Below is a summary table of the current analyst target prices discussed above:

Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target
SPDR S&P Biotech ETF XBI $84.59 $115.79 36.88%
Iovance Biotherapeutics Inc IOVA $8.25 $15.92 92.92%
Cytokinetics Inc CYTK $8.45 $15.86 87.66%
Abeona Therapeutics Inc ABEO $15.85 $29.71 87.47%

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.

The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on IOVA — FREE
Get the latest Zacks research report on CYTK — FREE
Get the latest Zacks research report on ABEO — FREE

More from Stocks

My Gut Says the Risk in Macy's Is to the Downside

My Gut Says the Risk in Macy's Is to the Downside

Beazer's Big Jump Builds Case for My Contrarian View on Sagging Housing Stocks

Beazer's Big Jump Builds Case for My Contrarian View on Sagging Housing Stocks

Cisco, Macy's, Boeing, Tilray and Snap - 5 Things You Must Know

Cisco, Macy's, Boeing, Tilray and Snap - 5 Things You Must Know

Jim Cramer: Don't Underestimate the China Tariff Risk

Jim Cramer: Don't Underestimate the China Tariff Risk

Price Action Demands Caution, but Watch the Bull Narrative

Price Action Demands Caution, but Watch the Bull Narrative